Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Arena Pharma says cannabinoid receptor-targeting olorinab could help treat the pain associated with Crohn’s disease.
The biotech changed its plans because its phase 3 overall response rate data “were not sufficiently mature to conduct the analysis.”
Ceribell raised $35 million for its rapid-response EEG headband that quickly diagnoses patients suspected of having seizures with no visual symptoms.
The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.
The trade war between the U.S. and China has grown, with tariffs now reaching over $4.75 billion in U.S. medical device exports to the country.
Morphic Therapeutic brought in $80 million to carry its two lead integrin-targeting programs through their clinical proof-of-concept studies.
AzurRx Biopharma's lead asset, a recombinant lipase designed to treat a condition linked to chronic pancreatitis, met its endpoints in a phase 2a trial.
Cynata Therapeutics found that mesenchymal stem cells can mute severe immune reactions to CAR-T treatments.
Akcea reported topline data showing its hyperlipoproteinemia drug lowered lipoprotein(a) levels in a phase 2 study in patients with cardiovascular disease.
AnaptysBio has positive data for its lead drug etokimab in a third indication, adding asthma to earlier wins in peanut allergy and atopic dermatitis.